Dr. Robert Risinger, Chief Medical Officer, Neuroscience at BioXcel Therapeutics, a biopharmaceutical company that uses artificial intelligence (AI) to identify drug targets and develop drugs in neuroscience and immuno-oncology, discusses the company’s lead product, IGALMI™ (dexmedetomidine), a sublingual film used to treat agitation associated with schizophrenia or bipolar disorder and three more compounds in earlier phases of development: BXCL501, BXCL502, and +BXCL501.

Dr. Risinger has extensive experience leading clinical development from first in human through Phase 1-4 clinical trials to create a successful commercial product. His expertise includes designing and executing high quality translational studies within Phase 1 and 2 that provide insight and rapidly navigate development to successful registration trials. Prior to joining BioXcel Therapeutics, Dr. Risinger served as Vice President of Clinical Development at NeuroRx Pharmaceuticals and Senior Medical Director, Clinical Development, at Alkermes. In addition, he held roles of increasing responsibility at Bristol Myers Squibb, Ortho-McNeill Janssen Medical Affairs, and Johnson & Johnson.   Dr. Risinger also served as Assistant Professor of Psychiatry and Behavioral Medicine at the Medical College of Wisconsin, and as Staff Psychiatrist as a Major in the U.S. Air Force. He has a B.S. in Chemistry and Biology from Allegheny College and M.D. from the University of Pittsburgh School of Medicine.

Liked it? Take a second to support healthprofessionalradio on Patreon!